New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
07:47 EDTWAG, AUXL, CAH, EBS, HCA, HLS, JNJ, PFE, TSRO, UHS, ZIOPMizuho to hold a conference
USA Healthcare Corporate Access Day is being held in New York on May 6.
News For WAG;UHS;TSRO;PFE;JNJ;HLS;HCA;EBS;CAH;AUXL;ZIOP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
October 9, 2014
08:49 EDTAUXLEndo sees low-double digit revenue growth with Auxilium portfolio
Subscribe for More Information
08:37 EDTAUXLEndo expects Auxilium acquisition immediately accretive post close
Endo (ENDP) says the deal will provided expected annual run rate synergies of up to $175M by the first year after closing versus Auxilium's (AUXL trailing 12-month actuals as of June 30. Says synergies include Auxilium's $75M reduction in annual operating expenses previously announced. Says the deal is expected to "significantly'" enhance Endo's branded pharmaceutical business with the addition of Auxilium's men's health products and development portfolio. Says the agreement is designed to "accelerate growth" and maximize value of Auxilium's products by leveraging strengths of combined company. Says combined company will be "well positioned" to drive organic growth for branded pharmaceutical business. Says deal creates a "strong" margin profile and an enhanced near-and long-term revenue growth profile. Comments taken from the company's slide presentation regarding its combination with Auxilium.
07:49 EDTAUXLEndo and Auxilium host a joint conference call
Subscribe for More Information
07:30 EDTAUXLQLT Inc. says re-engaging assessment of options after Auxilium deal ended
Subscribe for More Information
06:52 EDTAUXLQLT Inc. merger with Auxilium terminated for superior proposal from Endo
Subscribe for More Information
06:32 EDTAUXLEndo to acquire Auxilium in cash, stock transaction for approximately $2.6B
Endo (ENDP) and Auxilium Pharmaceuticals (AUXL) announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction. The boards of both companies have unanimously approved the transaction, which is valued at $2.6B, including the repayment and assumption of debt. The transaction will include an election mechanism for Auxilium stockholders to elect cash and stock, all-stock or all-cash consideration, subject to proration in accordance with the terms of the definitive agreement. The per share consideration represents a premium of 55% to Auxilium's closing price on September 16, the day Endo made public its proposal for Auxilium. Subject to aggregate cash and equity consideration limits, Auxilium stockholders may elect one of three options with respect to transaction consideration: 100% equity which equates to 0.488 Endo shares per Auxilium share, 100% cash which equates to $33.25 per Auxilium share or a standard election of an equal mix of $16.625 in cash and 0.244 Endo shares per Auxilium share. The total cash consideration will not exceed 50% of the total equity value and the equity consideration will not exceed 75% of the total equity value. The transaction is expected to close in 1H15 and is subject to the approval of Auxilium's stockholders, regulatory approval in the U.S. and certain other jurisdictions, and other customary closing conditions.
06:31 EDTAUXLEndo to acquire Auxilium in cash, stock transaction for approximately $2.6B
Subscribe for More Information
October 8, 2014
10:55 EDTPFELeerink pharmaceuticals analyst holds an analyst/industry conference call
Analysts discuss prospects for drugs that raise HDL cholesterol, effects of CETP mechanism, expectations for REVEAL data and the potential place for CETP inhibitors in a crowded hypersholesterolemia landscape on an Analyst/Industry conference call to be held on October 9 at 11 am.
08:33 EDTCAHCardinal Health and Ohio State University complete $13M medical imaging facility
Cardinal Health , the Ohio State University and State of Ohio Third Frontier Commission have completed a five-year-long project to create a new, $13M molecular imaging pharmaceuticals center. The 27,000-square-foot facility will research and produce specialized pharmaceuticals called "imaging agents," which are injected into the body and seek out particular cellular functions that are indicative of specific disease processes. The new center supports more than 80 employees.
08:09 EDTPFEPfizer presents LP2086 Phase 2 study data
Pfizer announced it will present the results of a Phase 2, randomized study to evaluate co-administration of the company’s investigational meningococcal group B vaccine, bivalent recombinant LP2086, or rLP2086, with a licensed quadrivalent human papillomavirus vaccine at IDWeek 2014. Data demonstrated immune responses to both vaccines were generated after concomitant administration of bivalent rLP2086 and HPV4. Prespecified noninferiority criteria were met for the bivalent rLP2086 antigens studied and three of the four antigens for HPV4. Primary immunogenicity endpoints, measured after the third dose, included geometric mean titers against HPV antigens in Groups 1 and 3 and human complement serum bactericidal assay GMTs against meningococcal group B disease test strains in Groups 1 and 2. Secondary immunogenicity endpoints included the rate of seroconversion to HPV antigens. Safety of bivalent rLP2086 was assessed after concomitant administration with HPV4 or saline. The prespecified noninferiority criteria were met for three of four HPV antigens and both meningococcal group B disease test strains. Seroconversion for all four HPV antigens was achieved by 99% or more of the subjects for the groups that received HPV4 concomitantly with bivalent rLP2086 or with saline. More local reactions occurred following administration of bivalent rLP2086 compared with saline but the incidence of these reactions did not increase with subsequent vaccine administration. The rates of local and systemic reactions were comparable when bivalent rLP2086 was given with HPV4 to bivalent rLP2086 given alone.
07:19 EDTPFECBI to hold a conference
Subscribe for More Information
07:18 EDTPFEInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
06:02 EDTWAGWalgreen implied volatility of 23 at lower end of index mean range
Subscribe for More Information
October 7, 2014
12:57 EDTJNJJohnson & Johnson October volatility increases into Q3 and outlook
Subscribe for More Information
10:02 EDTTSROOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:48 EDTPFEU.S. Chamber of Commerce to hold a discussion
Subscribe for More Information
07:24 EDTJNJAlliance for Regenerative Medicine
Subscribe for More Information
06:08 EDTJNJJohnson & Johnson Remicade competition could come in 2016, says Wells Fargo
Subscribe for More Information
06:03 EDTHCA, UHSCMS readmission penalties increase in 2015, says Wells Fargo
Wells Fargo says CMS released the final 2015 IPPS payment penalties for hospital readmissions, with incremental earnings Impact of down 0.2% to down 1.9% at for-profit hospitals. The firm estimates Community Health Systems (CYH) and Tenet Health (THC) will see the largest incremental reimbursement reduction in 2015, equal to down 1.9% and down 1.4%, respectively. It notes 2015 is the third year of hospital readmission penalties with a maximum penalty of 3%, up from 2% in 2014 and 1% in 2013. Wells has Outperform ratings on Community Health and HCA Holdings (HCA), and Market Perform ratings on LifePoint Hospitals (LPNT), Tenet and Universal Health (UHS).
05:41 EDTTSROTESARO initiated with a Buy at Jefferies
Target $40.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use